期刊
ANGEWANDTE CHEMIE-INTERNATIONAL EDITION
卷 53, 期 44, 页码 11917-11920出版社
WILEY-V C H VERLAG GMBH
DOI: 10.1002/anie.201406897
关键词
antitumor agents; cancer; immunology; synthetic vaccines; Tn antigen
资金
- Labex Arcane [ANR-11-LABX-003]
- Ente Cassa di Risparmio di Firenze [ANR-12-JS07-0001-01]
- AIRC
- COSTaction [CM1102]
- PHC Galileo Program
- Public Health Service Research NIH [EY14900, EY019896]
Tumor-associated carbohydrate antigens (TACAs) are key components of cancer vaccines. A variety of vaccines based on native TACAs such as alpha-Tn have shown immunogenicity and protection in preclinical animal studies, however, their weak immunogenicity, low in vivo instability, and poor bioavailability, have discouraged their further evaluations in clinical studies. A new improved vaccine prototype is reported. It is composed of four clustered Tn-antigen mimetics and a immunogenic peptide epitope that are conjugated to a cyclopeptide carrier. The immunization of mice with this vaccine 1) was safe, 2) induced a strong and long-lasting Tn-specific response with IgM/IgG antibodies able to recognize native carbohydrate antigens; 3) produced high titers of IgG1, IgG2a, and IgG3 antibodies; and 4) produced a significant antibodydependent regression of tumors and conferred protection. Altogether, these findings pave the way for the clinical development of safe and effective therapeutic vaccines against Tn-expressing cancers.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据